1. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp.
- Author
-
Wong G, Bienes KM, Xiii A, Fausther-Bovendo H, and Kobinger GP
- Subjects
- Humans, Animals, Disease Outbreaks, Antibodies, Neutralizing therapeutic use, Antibodies, Neutralizing immunology, Africa, Western epidemiology, Hemorrhagic Fever, Ebola drug therapy, Hemorrhagic Fever, Ebola immunology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal immunology, Ebolavirus immunology, Ebolavirus drug effects, Antibodies, Viral therapeutic use, Antibodies, Viral immunology
- Abstract
In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013-2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013-2016 outbreak and advancing to randomized controlled trials into the 2018-2020 African outbreak. We end with a brief discussion of the hurdles and promise toward mAb therapeutic use against infectious disease., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF